GLP-1 Medications Show Promise for Weight Loss in Schizophrenia But Effects Are Smaller Than in General Population
GLP-1 receptor agonists reduce weight in people with schizophrenia, but effect sizes are mostly smaller than in the general population, with six completed trials and three ongoing.
Quick Facts
What This Study Found
GLP-1 RAs decrease weight in schizophrenia patients, but effect sizes are mostly smaller than in the general population. Six trials completed, three ongoing, with future directions including dual agonists and early intervention.
Key Numbers
3-5 times higher prevalence of diabetes and obesity in schizophrenia patients; 20-year reduced lifespan compared to general population.
How They Did This
Narrative review of all completed and in-progress clinical trials of GLP-1 receptor agonists for weight management in people with schizophrenia.
Why This Research Matters
Antipsychotic-induced weight gain is a leading cause of medication non-adherence and reduced lifespan in schizophrenia. Effective weight management could improve both physical health and psychiatric outcomes in this vulnerable population.
The Bigger Picture
GLP-1 medications are transforming obesity treatment, but their effects in psychiatric populations may differ due to the complex metabolic effects of antipsychotic medications. Understanding these differences is critical for ensuring this vulnerable population benefits from these breakthroughs.
What This Study Doesn't Tell Us
Narrative review without meta-analysis; most completed trials are small; limited head-to-head comparisons; antipsychotic medication variability across studies; short trial durations; unclear whether weight benefits improve psychiatric outcomes or medication adherence.
Questions This Raises
- ?Why are GLP-1 RA weight loss effects smaller in schizophrenia — is it the antipsychotics or the disease?
- ?Could starting GLP-1 RAs simultaneously with antipsychotics prevent weight gain entirely?
- ?Will dual agonists like tirzepatide show larger effects in this population?
Trust & Context
- Key Stat:
- Smaller effects GLP-1 RA weight loss in schizophrenia vs general population across 6 completed trials
- Evidence Grade:
- Moderate evidence from multiple small clinical trials. Consistent direction of effect but smaller magnitude, with larger trials needed.
- Study Age:
- Published in 2024, with three additional trials ongoing that may provide stronger evidence.
- Original Title:
- GLP-1 receptor agonists and weight loss in schizophrenia - past, present, and future.
- Published In:
- Current opinion in psychiatry, 37(5), 363-369 (2024)
- Authors:
- Trott, Mike(2), Arnautovska, Urska(2), Siskind, Dan(3)
- Database ID:
- RPEP-09409
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can GLP-1 medications help with weight gain from psychiatric medications?
Yes — clinical trials show GLP-1 agonists do reduce weight in people with schizophrenia on antipsychotics, but the amount of weight loss is generally smaller than what's seen in people without schizophrenia. More research is ongoing.
When should GLP-1 medications be started for people on antipsychotics?
This review suggests that starting GLP-1 medications at the same time as antipsychotic treatment — to prevent weight gain rather than reverse it — could be more effective. Future trials are testing this preventive approach.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09409APA
Trott, Mike; Arnautovska, Urska; Siskind, Dan. (2024). GLP-1 receptor agonists and weight loss in schizophrenia - past, present, and future.. Current opinion in psychiatry, 37(5), 363-369. https://doi.org/10.1097/YCO.0000000000000952
MLA
Trott, Mike, et al. "GLP-1 receptor agonists and weight loss in schizophrenia - past, present, and future.." Current opinion in psychiatry, 2024. https://doi.org/10.1097/YCO.0000000000000952
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 receptor agonists and weight loss in schizophrenia - p..." RPEP-09409. Retrieved from https://rethinkpeptides.com/research/trott-2024-glp1-receptor-agonists-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.